The counseling african americans to control hypertension (caatch) trial: baseline demographic, clinical, psychosocial, and behavioral characteristics by Fernandez, Senaida et al.
RESEARCH Open Access
The counseling african americans to control
hypertension (caatch) trial: baseline demographic,
clinical, psychosocial, and behavioral
characteristics
Senaida Fernandez
1, Jonathan N Tobin
2,3, Andrea Cassells
2, Marleny Diaz-Gloster
2, Chamanara Kalida
2 and
Gbenga Ogedegbe
1*
Abstract
Background: Effectiveness of combined physician and patient-level interventions for blood pressure (BP) control in
low-income, hypertensive African Americans with multiple co-morbid conditions remains largely untested in
community-based primary care practices. Demographic, clinical, psychosocial, and behavioral characteristics of
participants in the Counseling African American to Control Hypertension (CAATCH) Trial are described. CAATCH
evaluates the effectiveness of a multi-level, multi-component, evidence-based intervention compared with usual
care (UC) in improving BP control among poorly controlled hypertensive African Americans who receive primary
care in Community Health Centers (CHCs).
Methods: Participants included 1,039 hypertensive African Americans receiving care in 30 CHCs in the New York
Metropolitan area. Baseline data on participant demographic, clinical (e.g., BP, anti-hypertensive medications),
psychosocial (e.g., depression, medication adherence, self-efficacy), and behavioral (e.g., exercise, diet) characteristics
were gathered through direct observation, chart review, and interview.
Results: The sample was primarily female (71.6%), middle-aged (mean age = 56.9 ± 12.1 years), high school
educated (62.4%), low-income (72.4% reporting less than $20,000/year income), and received Medicaid (35.9%) or
Medicare (12.6%). Mean systolic and diastolic BP were 150.7 ± 16.7 mm Hg and 91.0 ± 10.6 mm Hg, respectively.
Participants were prescribed an average of 2.5 ± 1.9 antihypertensive medications; 54.8% were on a diuretic; 33.8%
were on a beta blocker; 41.9% were on calcium channel blockers; 64.8% were on angiotensin converting enzyme
(ACE) inhibitors/angiotensin receptor blockers (ARBs). One-quarter (25.6%) of the sample had resistant hypertension;
one-half (55.7%) reported medication non-adherence. Most (79.7%) reported one or more co-morbid medical
conditions. The majority of the patients had a Charlson Co-morbidity score ≥ 2. Diabetes mellitus was common
(35.8%), and moderate/severe depression was present in 16% of participants. Participants were sedentary (835.3 ±
1,644.2 Kcal burned per week), obese (59.7%), and had poor global physical health, poor eating habits, high health
literacy, and good overall mental health.
Conclusions: A majority of patients in the CAATCH trial exhibited adverse lifestyle behaviors, and had significant
medical and psychosocial barriers to adequate BP control. Trial outcomes will shed light on the effectiveness of
evidence-based interventions for BP control when implemented in real-world medical settings that serve high
numbers of low-income hypertensive African-Americans with multiple co-morbidity and significant barriers to
behavior change.
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Hypertension affects approximately 65 million adults
in the United States [1], and disproportionately affects
African Americans in terms of prevalence, treatment,
and control rates compared to whites [2,3]. These dis-
parities may explain the poorer adverse hypertension-
related outcomes in African Americans [4]. The cardi-
ovascular benefits of blood pressure (BP) control are
well-documented [5], as are the utility of patient- and
provider-centered interventions in promoting BP con-
trol [6-9]. Lifestyle interventions of reduced sodium
intake [7,10] and other dietary modifications
(increased consumption of fiber, fruits, vegetables,
and low fat dairy; reduced consumption of saturated
and total fat) [11], and increased physical activity and
weight loss [6] have resulted in significant BP reduc-
tion. While these interventions have proven effica-
cious in clinical trials, and although there are many
community-based interventions that engage African
Americans (and are often conducted in low-income
communities), their effectiveness remains largely
untested among hypertensive African Americans who
receive care in low-resource settings such as Commu-
nity Health Centers (CHCs).
The Counseling African Americans to Control Hyper-
tension (CAATCH) trial [12] was designed to evaluate,
in a cluster randomized trial, the effectiveness of a
multi-level, multi-component, evidence-based interven-
tion compared to usual care (UC) in improving BP con-
trol in hypertensive African Americans who receive care
in CHCs. The trial targets barriers to optimal hyperten-
sion control at the patient, provider, and practice levels
in a large cohort of African American adults (n =
1,039) [12]. As such, this trial has the potential to
expand our understanding of barriers and facilitators of
intervention implementation in ‘real-world’ clinical set-
tings, as well as the effectiveness of lifestyle interven-
tions in previously understudied and underserved
populations. This paper describes the demographic,
clinical, psychosocial, and behavioral characteristics of
CAATCH trial participants in order to highlight some
of the patient-related barriers to hypertension control
present in this sample.
Methods
Study Design and Setting
A detailed description of the rationale, design, and
methods of this trial has been published elsewhere [12].
The study protocol was approved by the Institutional
Review Boards (IRBs) of Columbia University, New York
University, and Clinical Directors Network (CDN), and
all participants provided informed consent to participate.
Briefly, CAATCH is a two-arm, cluster-randomized con-
trolled trial (RCT) implemented in 30 CHCs, with 15
sites randomly assigned to the intervention condition
(IC) and 15 to UC.
Participants
The participants included 1,039 African American adult
men and women. Patients were eligible for the study if
they: self-identified as black or African American; were
at least 18 years old, were receiving care at the partici-
pating CHC for at least six months prior to enrollment;
had a diagnosis of hypertension (HTN), were taking at
least one anti-hypertensive medication, and had uncon-
trolled BP at the time of enrollment based on standar-
dized measurement at study visit (systolic BP (SBP) ≥
140 mm Hg or diastolic BP (DBP) ≥ 90 mmHg; for
those with diabetes or kidney disease, SBP ≥ 130 mm
Hg or DBP ≥ 80 mm Hg). Additional details on inclu-
sion and exclusion criteria have been published else-
where [12]. Figure 1 shows the flow of patients through
the study in a CONSORT [13] diagram.
Interventions
The intervention was implemented at the practice level,
such that all physicians and patients at a given site were
in the same treatment condition: IC or UC. Within the
IC sites, the CAATCH intervention is comprised of
three components targeted at patients (interactive com-
puterized hypertension education, home BP monitoring,
and monthly behavioral counseling on lifestyle modifica-
t i o n )a n dt w oc o m p o n e n t st a r g e t e da tp h y s i c i a n s
(monthly CME-accredited case rounds based on JNC-7
guidelines [5], chart audit and provision of feedback on
clinical performance, and patients’ home BP readings).
Additional details on the intervention and its delivery
are described elsewhere [12].
Objectives
The goal of CAATCH was to evaluate, in cluster rando-
mized trial, the effectiveness of a multi-level, multi-com-
ponent, evidence-based intervention compared to UC in
improving BP control among hypertensive African
Americans who receive care in CHCs. We hypothesize
that patients randomized to the IC will have, compared
to those in the UC condition: a higher BP control rate
at 12 months; greater reduction in both SBP and DBP at
12 months; and a higher rate of maintenance of inter-
vention effect one year after completion of the trial. In
addition, the IC will be more cost-effective in improving
BP control rate at 12 months compared to UC.
Outcomes
The primary outcome was the proportion of patients
with adequate BP control at 12 months; and the mainte-
nance of intervention effects one year after the trial. BP
was defined as uncontrolled if the average BP ≥ 140 mm
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ity) OR average SBP ≥ 130 mm Hg or DBP ≥ 80 mm
Hg (for those with diabetes or kidney disease). The sec-
ondary outcomes are within-patient change in BP from
baseline to 12 months, and the cost effectiveness of
intervention at 12 months.
Data collection
Data collection and study measurements were per-
formed by trained research assistants (RAs) via inter-
views, direct measurements, and chart review. A
complete listing of all measures and details of assess-
ment protocol has been published elsewhere [12]. At
baseline, three BP readings were taken by trained RAs
using a validated automated BP monitor (BPTru, Model
BPM-300; BpTRU Medical Devices, Coquitlam, BC,
Canada) with the patient seated comfortably and
following American Heart Association (AHA) guidelines
[14]. The average of the three readings was used as the
measure for baseline assessment. Psychosocial and beha-
vioral characteristics were assessed with validated self-
report measures and included medication adherence (4-
item Morisky Scale) [15], self-efficacy (Medication
Adherence Self-Efficacy Scale; MASES) [16], health lit-
eracy (Rapid Estimate of Adult Literacy in Medicine;
REALM) [17], dietary intake (Rapid Eating Assessment
for Patients; REAP) [18], physical activity (Paffenbarger
Physical Activity Scale) [19], daytime sleepiness
(Epworth Sleepiness Scale) [20], depression (Patient
Health Questionnaire-9; PHQ-9) [21], and general physi-
cal and mental health (version one of the 12-Item Short
Form Health Survey; SF-12) [22]. At the CHC site level,
data were gathered on whether CHCs utilized electronic
health records (EHRs), and whether they were part of
Figure 1 Flow of participants through study.
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(HRSA) Health Disparities Collaboratives http://www.
healthcarecommunities.org. The HRSA sponsored
Health Disparities Collaboratives (HDCs) use the struc-
ture of the Chronic Care Model (CCM), which is an
organizational approach to caring for people with
chronic disease who are seen in a primary care setting.
The system is population-based, and creates practical,
supportive, evidence-based interactions between an
informed, activated patient and a prepared, proactive
practice team; it identifies six major categories that
must be addressed to achieve substantial change, includ-
ing the healthcare organization, community resources
and policies, self-management support, decision support,
delivery system design, and clinical information systems
[23].
Power analysis and sample size
The design for the CAATCH trial was based on power
calculations for the proposed analysis of differential
changes in office SBP and DBP between IC and UC
sites (CHCs). These calculations were based on post-
intervention data available from Phase one of the medi-
cation Adherence and Blood Pressure Control (ABC)
trial, which was conducted by this research group in
several of the same CHCs [24]. BPs for those in the
ABC trial home blood pressure monitoring (HBPM)
intervention (n = 137) were compared to those in the
UC group (n = 80) in nine sites, and office BPs
decreased substantially in both conditions (SBP/DBP
decreased 12.0/6.0 mmHg in HBPM versus 8.7/3.8
mmHg in UC). Of note, they decreased more (3.3/2.2
mmHg, p = 0.053/0.078) in the HBPM condition. Clus-
tered sampling due to patients being nested within sites
was controlled for, yielding estimates of the between-site
and within-site variances in treatment effect (5.13 and
154.21 for SBP, and 1.72 and 86.35 for DBP). Sites were
the primary unit of analysis, given that sites are rando-
mized to treatment condition. To estimate the number
of sites required, the within-treatment, between-site var-
iance of site-level mean change scores was first esti-
mated. This is estimated as the between-site (true)
variance plus the sampling variability of the site mean.
For SBP, this was 5.13 ± 154.21/Nsite, and for DBP it
was 1.72 ± 86.35/Nsite, where Nsite is the number of
patients per site. We initially planned for 30 patients per
site, yielding variance estimates of 10.28 and 4.60 for
site-level mean changes in SBP and DBP; taking square
roots gives standard deviation estimates of 3.21 and
2.14. These estimates and the usual power calculations
for a t-test were used to determine the number of sites
needed to have adequate power to detect a specified
effect size. With a total of 30 sites (with 30 patients at
each site), 15 assigned to each condition (IC and UC),
these estimates implied that there would be 80% and
81% power to detect SBP and DBP treatment effects
equal to the HBPM effect reported above (using a 2-
tailed, 0.05-level test). Because of the multifaceted nat-
ure of the intervention that was implemented in this
study, it is reasonable to anticipate treatment effects of
at least 4 mm Hg for SBP and 3 mm Hg for DBP. The
estimated power to detect effects of this magnitude is
91% and 96%, respectively. Thus, based on this power
analysis, we planned to randomize 30 sites (1:1). Because
we anticipated approximately a 15% rate of attrition, the
enrollment target was set at 1,058 patients from these
sites, which would yield a final sample of 900 patients
who complete the study (an average of 30 per site).
Analytic plan
The CAATCH trial has three nested levels of sampling:
site, physician, and patient. Sites were matched for size
(large/medium versus small), creating 15 matched pairs.
Within each pair, one site was randomly assigned to IC
and the other to UC. Due to a variety of unspecified fac-
tors, it was assumed that patients from the same site,
and perhaps also patients having the same physician,
would be somewhat more similar than randomly
selected patients attending different CHCs or having dif-
ferent physicians. This implies correlated residuals due
to ‘clustered sampling,’ that will be controlled in the pri-
mary outcome analysis by treating both CHC and clini-
cian within CHC as random factors. Maximum
likelihood estimates, approximate standard errors, and
multi-level modeling statistical tests for primary out-
come analysis will be obtained using PROC MIXED
(SAS) [25,26]. The comparison of treatment groups with
respect to dichotomous or ordinal measures (e.g., gender
or smoker) will be performed using the MIXOR soft-
ware [27,28], which estimates a logistic regression (with
random effects). The clustered sampling effects asso-
ciated with CHC and physician will be adjusted for in
the equation. As appropriate, the model will be further
augmented to include both person-level covariates (e.g.,
gender) and time-varying covariates (e.g., body mass
index). As stated, the primary hypothesis concerns the
treatment by time interaction.
Results
CHC characteristics
The 30 CHCs serve primarily low-income, African
American populations. The median household yearly
income in CHC zip codes was $32,499 (SD = $17,054)
and mean percentage of African American adults in
CHC zip codes was 53% (SD = 27%). A majority of the
sites in the trial were located in metropolitan New York
City (NYC) (73.30%), upstate New York (13.30%), and
northern New Jersey (13.30%). The IC and UC sites
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mean number of patients seen at the CHCs was 10,432
patients (SD = 13, 157) with 33.33% of sites classified as
‘large’ or ‘extra large’ CHC. Only a quarter of sites uti-
lized EHRs, and less than one-half were participating in
the HRSA Health Disparities Collaborative (see Table 1).
Clinician characteristics
CAATCH clinicians (n = 94) were middle-aged (M =
47.0 ± 14.1 years); 57% female; 43% African American,
24% White, 9% Hispanic; 57% were U.S. Born; had MD/
DO degree (75%); had worked in their CHC an average
of 8.0 ± 6.5 years. There were an average of 4.4 clini-
cians per CHC.
Demographic characteristics
CAATCH participants were middle-aged (M = 56.9 ±
12.1 years), primarily female (71.6%), high-school edu-
cated (62.4%) and U.S. born (74.6%). Participants who
were foreign-born had lived in the U.S. an average of
20 ± 12.4 years. One-half (54.0%) were insured
through Medicaid and Medicare. As compared to UC,
IC participants were more likely to be low-income (IC
= 78.6% versus UC = 65.8%, p< 0.01) and have no
health insurance (IC = 11.3% versus UC = 3.4%, p
<0.01; see Table 2).
Clinical characteristics
Baseline mean SBP and DBP were 150.7 ± 16.7 mm Hg
and 91.0 ± 10.6 mm Hg, respectively. SBP was signifi-
cantly higher in the UC group (152.1 ± 16.8) compared
to the IC group (149.3 ± 16.5, p = 0.007). There were
no between group differences for DBP. Resistant hyper-
tension, defined as any patient taking at least three anti-
hypertensive medications including a diuretic, was
present among 25.6% of participants. Over one-half of
the participants were obese, and an additional one-quar-
ter was overweight. Most (79.7%) reported one or more
co-morbid conditions, with over one-half (55.1%)
reporting two or more, and a sample mean Charlson
Comorbidity score of 2.5 ± 2.5. Diabetes mellitus was
the most commonly reported co-morbid condition
(35.8%), and congestive heart failure (CHF) was more
common among UC (13.5%) than IC (7.5%) participants
(p = 0.002; See Table 3).
CAATCH participants were taking an average of 2.5
antihypertensive medications, with over one-third of the
sample taking three or more medications. Over one-half
of the participants were on a diuretic (alone or in com-
bination with other drugs); the most common antihy-
pertensive medication prescribed for patients in this
study was ACE/ARBs with over two-thirds of the
patients, and a little over one-half were prescribed
diuretic alone on in combination with other drugs (see
Table 4).
Psychosocial and behavioral characteristics
One-half of CAATCH participants reported medication
non-adherence to their antihypertensive medication
(55.7%), with a larger proportion of non-adherence in
the UC group (63.1%) compared to the IC group (48.7%,
p< 0.01). Self-efficacy for medication taking was lower in
the UC group (M =2 . 2±0 . 6 )t h a nt h eI Cg r o u p( M =
2.3 ± 0.6, p = 0.02). With regards to health literacy, a
smaller proportion of UC participants (54.1%), com-
p a r e dt oI Cp a r t i c i p a n t s( 6 0 . 8 % )d e m o n s t r a t e dh i g h
health literacy (61 to 66 points range) on the REALM,
(p = 0.04). Differences in eating behaviors were also
found between groups, with IC participants engaging in
slightly less healthy eating (M =1 . 7±0 . 8 )c o m p a r e dt o
UC participants (M = 1.9 ± 0.8, p = 0.006).
Assessments of depression (PHQ-9), physical activity
(Paffenbarger Physical Activity Scale) and general mental
and physical functioning (SF-12) suggest that while
mental health scores were generally within normal lim-
its, on average, participants experienced some limita-
tions in their physical functioning. The mean score on
the Mental Component Summary (MCS) of the SF-12
Table 1 Community Health Center (CHC) Characteristics at Baseline
Characteristic Total
(n = 30)
Intervention Group
(n = 15)
Usual Care Group
(n = 15)
p
NYC 73.3 66.7 80.00 0.08
Upstate NY 13.3 6.7 20.00
NJ 13.3 26.7 0.00
Size/#Users (SD) 10,432 (13,157) 9,311 (8,234) 11,553 (16,973) 0.65
% Large CHC 33.3 33.3 33.3 1.0
% Using Electronic Health Records (EHR) 26.7 20.0 33.3 0.41
% Participating in HRSA Health Disparities Collaboratives (HDC) 43.3 46.7 40.0 0.71
Median Household Income in Zip Code 32,499 (17,054) 28,352 (11,196) 36,645 (20,982) 0.19
Mean% African American Adults in Zip (SD) 52.6 (27.2) 57.1 (27.5) 48.3 (27.2) 0.38
Note. # Users = total number of patients across all divisions of care. HRSA = Health Resources and Services Administration.
Fernandez et al. Implementation Science 2011, 6:100
http://www.implementationscience.com/content/6/1/100
Page 5 of 13was 48.0 ± 11.2. When comparing SF-12 MCS mean
scores between groups, the UC group scored signifi-
cantly lower (M = 47.1 ± 11.6) in overall mental health
than the IC group (M = 48.7 ± 10.8, p = 0.03). Mean
scores on PHQ-9 depression measure indicated that the
UC group (M =5 . 4±4 . 7 )s c o r e di nt h em i l d l y
depressed range (PHQ-9 score ≥ 5) [21] and signifi-
cantly higher than the IC group (M =4 . 5±4 . 6 ,p =
0.005). Approximately sixteen percent of the participants
reached the cut-off for moderate/severe major depres-
sive disorder (PHQ-9 score ≥ 10) [21]. The Physical
Component Summary (PCS) score of the SF-12 was
42.3 ± 10.4, and the UC group scored significantly lower
(M = 41.6 ± 10.9) on the scale than the IC group (M =
43.0 ± 9.8, p = 0.04). Paffenbarger Physical Activity
Scale mean scores indicated that CAATCH participants
were sedentary, burning on average 835.3 ± 1,644.2 Kcal
per week in physical activity. While sleep quality scores
(M = 7.0 ± 4.7) fell within the Epworth Sleepiness Scale
(ESS) normal range (0 to 9) [20,29], one-fifth (20.9%)
experienced problematic levels of daytime sleepiness, as
indicated by scores of 10 or greater on the scale (see
Table 5).
Discussion
In this paper we describe the baseline characteristics of
A f r i c a nA m e r i c a np a t i e n t se n r o l l e di nt h eC A A T C H
trial, a cluster RCT multi-level, practice-based, BP con-
trol trial among a sample of CHCs with a rich diversity
of demographic, clinical, psychosocial, and behavioral
Table 2 Demographic Characteristics of Participants at Baseline
Characteristic Total
(n = 1,039)
Intervention Group
(n = 529)
Usual Care
Group
(n = 510)
p
Age in Years (mean ± sd; n = 1,026) 56.9 ± 12.1 56.7 ± 11.5 57.0 ± 12.8 0.72
Age ≥ 65 Years (%; n = 1,026) 26.5 26.8 26.2 0.85
Gender (%; n = 1,014)
Female 71.6 69.3 74.0 0.10
Ethnicity (%; n = 953)
Non-Hispanic 93.3 94.3 92.2 0.21
Hispanic 6.7 5.7 7.8
Place of Birth (%; n = 941)
USA 74.60 76.4 72.6 0.18
Non-USA 25.40 23.6 27.4
Marital Status (%; n = 953)
Separated/Divorced/Widowed 44.7 48.0 41.3 0.07
Married 25.8 25.5 26.1
Never married 29.5 26.5 32.6
Education Level (%; n = 956)
≥ High School 62.4 59.9 65.2 0.14
< High School 36.9 39.7 34.0
None 0.6 0.4 0.9
Employment Status (%; n = 944)
Not employed 11.0 12.3 9.6 0.15
Retired or Homemaker 55.2 57.1 53.2
Employed: Part-time 13.6 12.1 15.1
Employed: Full-time 20.2 18.5 22.1
Income (%; n = 940)
< $20,000/year 72.4 78.6 65.8 < 0.01**
≥ $20,000/year 27.6 21.4 34.2
Insurance Status (%; n = 917)
Medicaid 35.9 38.7 32.9 < 0.01**
Medicare 12.6 12.6 12.8
Medicaid and Medicare 5.5 6.4 4.5
Private/HMO 19.0 13.8 24.4
None 7.4 11.3 3.4
Other# 19.6 17.2 22.1
Note. Data gathered through interview. #Category includes VA insurance; combination/multiple sources of coverage. *p < 0.05; **p < 0.01
Fernandez et al. Implementation Science 2011, 6:100
http://www.implementationscience.com/content/6/1/100
Page 6 of 13characteristics. Results from this trial will provide valu-
able information on interventions to promote BP con-
trol in a high-risk population of hypertensive African
Americans with uncontrolled BP.
There were a number of patient-level barriers to
hypertension control among the CAATCH sample at
baseline, including low-income, significant co-morbidity,
sedentary lifestyle, smoking, overweight, and obesity.
This sample had a considerably lower mean income
compared to patients in large-scale epidemiological stu-
dies, such as the multi-ethnic Dallas Heart Study [30,31]
and the Jackson Heart Study [32,33]. When compared
to other large-scale trials in hypertensive African Ameri-
cans, CAATCH participants were more likely to be in
Table 3 Clinical Characteristics of Participants at Baseline
Characteristic Total
(n = 1,039)
Intervention Group
(n = 529)
Usual Care Group
(n = 510)
p
Baseline BP^ (mean ± sd; n = 1,039)
SBP 150.7 ± 16.7 149.3 ± 16.5 152.1 ± 16.8 < 0.01**
DBP 91.0 ± 10.6 90.8 ± 10.7 91.2 ± 10.5 0.54
Resistant Hypertension† (%; n = 912) 25.6 27.8 23.6 0.15
Smoking Status† (%; n = 939)
Current 29.8 32.0 27.5 0.08
Former 20.9 22.3 19.4
Never 49.3 45.8 53.1
Body Mass Index† (%; n = 647)
Mean (SD), kg/m
2 32.5 (7.9) 32.6 (7.6) 32.4 (8.4) 0.77
Overweight 26.3 28.3 23.2 0.15
Obese 59.7 59.9 59.3
Number of Co-morbid Conditions‡ (%; n = 929)
0 20.3 18.3 22.3 0.03*
1 24.6 28.1 20.9
2 to 3 35.6 36.2 35.0
> 3 19.5 17.3 21.8
Comorbid Conditions‡ (%; n = 964)
Charlson Score (mean ± sd; n = 965) 2.5 ± 2.5 2.4 ± 2.5 2.5 ± 2.5 0.70
Chronic Kidney Disease 2.5 2.4 2.6 0.87
Myocardial Infarction 7.4 6.9 7.9 0.53
Congestive Heart Failure 10.4 7.5 13.5 < 0.01**
Stroke 10.9 9.9 12.0 0.30
Diabetes Mellitus 35.8 37.2 34.3 0.35
Note. Data gathered through: ^direct observation, †chart review, ‡interview. BP = Blood Pressure; HTN = Hypertension. *p < 0.05; **p < 0.01
Table 4 Blood Pressure Medications at Baseline
Total
(n = 1,039)
Intervention Group
(n = 529)
Usual Care
Group
(n = 510)
p
Number of Drugs in Hypertension Regimen (%; n = 907)
1 32.7 30.1 35.8
2 30.1 29.1 31.3
3 18.0 20.4 15.1
≥ 4 19.2 20.4 17.8 0.08
On a Diuretic (%; n = 912) 54.8 54.6 55.1 0.86
On a Beta Blocker (%; n = 912) 33.8 30.4 37.7 0.02*
If on a 2-Drug Regimen (%; n = 273), Percent on a Diuretic 57.9 57.3 58.5 0.85
If on a 3-Drug Regimen (%; n = 163), Percent on a Diuretic 63.2 65.0 60.3 0.55
If on a 3-Drug or Greater Regimen (n = 337), Percent on a Diuretic 70.0 68.5 72.3 0.46
If on a 2-drug Regimen (n = 273), Percent on ACE+CCB 6.2 6.3 6.2 0.96
Note. Data gathered through chart review.
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pants were heavier than those in the Dallas Heart Study
[30], Jackson Heart Study [33], in Dietary Approaches to
Stop Hypertension (DASH), Hypertension Improvement
Project (HIP), and PREMIER trials [6,11,34]. Obesity
rates reported for African Americans in the National
Health and Nutrition Examination Survey (NHANES)
were only 45% [35,36], compared to over two-thirds
reported in CAATCH. Similar to published data on
medication adherence [15,37-39], one-half of the
CAATCH participants reported non-adherence, and
they experienced diabetes and cardiovascular disease at
rates higher than samples in large scale epidemiological
trials such as the Jackson Heart Study [33]. In fact,
CAATCH participants reported higher co-morbid medi-
cal conditions, which are recognized as significant bar-
riers to BP control [40]. Physical activity levels in the
CAATCH sample were very low, with most of the parti-
cipants characterized as sedentary or insufficiently
active. This a higher proportion than rates noted in the
most recent NHANES data [41]. A noteworthy finding
is that prevalence of smoking in the CAATCH trial was
higher than those in the Jackson Heart Study [33], the
Dallas Heart Study [30], and recent NHANES data on
smoking among overweight and obese adults [41].
Further attention is warranted for several of the
CAATCH sample’s psychosocial and behavioral charac-
teristics. CAATCH participants reported a moderate
level of self-confidence in their ability to take antihyper-
tensive medications (as measured by the MASES) [16],
and a low level of healthy eating (as measured by the
REAP) [18]. While the average general mental health
score (Mental Component Summary of the SF-12) [22]
of participants fell within normal range of population
based norms, the UC participants scored in the mildly
depressed range (as assessed by the PHQ-921). Further-
more, participants reported limitations in general physi-
cal functioning (Physical Component Summary of the
SF-12) [22]. Though, on average, participants scored
within the normal range on an index of sleep quality
[20,29], problematic levels of daytime sleepiness
(Epworth Sleep Scale score ≥ 10) were present among
one-fifth. This rate is higher than the prevalence of day-
time somnolence observed in recent NHANES data [42],
Table 5 Psychosocial and Behavioral Characteristics of Participants at Baseline
Characteristic Total
(n = 1,039)
Intervention Group
(n = 529)
Usual Care
Group
(n = 510)
p
Medication Non-adherence (%; n = 961) 55.7 48.7 63.1 < 0.01**
Medication Adherence Self-Efficacy Scale (MASES; mean ± sd; n = 787) 2.2 ± 0.6 2.3 ± 0.6 2.2 ± 0.6 0.02*
Rapid Estimate of Adult Literacy in Medicine (REALM; mean ± sd; %; n = 889) 56.9 ± 13.2 57.3 ± 12.8 56.4 ± 13.6 0.28
3
rd Grade (0 to 18) 3.5 3.0 4.0 0.04*
4
th to 6
th Grade (19 to 44) 8.8 9.9 7.5
7
th to 8
th Grade (45 to 60) 30.1 26.3 34.4
9
th Grade and Greater (61 to 66) 57.6 60.8 54.1
Rapid Eating Assessment for Patients
(REAP; mean ± sd; n = 930)
1.8 ± 0.8 1.7 ± 0.8 1.9 ± 0.8 < 0.01**
Paffenbarger Physical Activity Scale (mean ± sd; %; n = 951) 835.3 Kcal ± 833 Kcal ± 837.8 Kcal ± 0.97
1,644.2 Kcal 1,856.8 Kcal 1,388.9 Kcal 0.87
Sedentary (< 500 Kcal/week) 54.1 54.3 53.8
Insufficiently Active (500 to 999 Kcal/week) 25.1 24.4 25.8
Regularly Active (≥ 1,000 Kcal/week) 20.8 21.3 20.4
Epworth Sleepiness Scale (mean ± sd; %; n = 949) 7.0 ± 4.7 6.9 ± 4.8 7.2 ± 4.6 0.46
Normal (≥ 10) 79.1 80.2 78.0 0.40
Excessive Daytime Sleepiness (> 10) 20.9 19.8 22.0
Patient Health Questionnaire-9 (mean ± sd; %; n = 850) 4.9 ± 4.7 4.5 ± 4.6 5.4 ± 4.7 < 0.01**
Minimal (0 to 4) 56.2 59.4 52.8 0.28
Mild (5 to 9) 28.1 26.3 30.1
Moderate (10 to 14) 10.9 10.4 11.5
Moderately Severe (15 to 19) 4.1 3.2 5.1
Severe (20 to 27) 0.6 0.7 0.5
SF-12 (mean ± sd; n = 939)
PCS-12 42.3 ± 10.4 43.0 ± 9.8 41.6 ± 10.9 0.04*
MCS-12 48.0 ± 11.2 48.7 ± 10.8 47.1 ± 11.6 0.03*
Note. Data gathered through interview. PCS-12 = Physical Component Summary; MCS-12 = Mental Component Summary. *p < .05; **p < 0.01
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Sleep Heart Health Study [43]. The problematic daytime
sleepiness observed in CAATCH participants may be
due in part to the higher prevalence of obesity, which is
a major risk factor for obstructive sleep apnea [44,45].
One-quarter of CAATCH participants had resistant
hypertension (defined as any patient with uncontrolled
BP who is taking at least three antihypertensive medica-
tions, including a diuretic). While thiazide type diuretics
are the recommended initial pharmacological treatment
[5,46], only one-half of the CAATCH sample had been
prescribed one. However, this percentage is higher than
t h ed i u r e t i cr a t er e p o r t e df o rap o p u l a t i o no fh y p e r t e n -
sive patients from a large managed care organization,
located in the southeastern United States, based on pre-
scription fill data two years following publication of the
JNC-7 guidelines [46].
One of the most striking aspects of the CAATCH trial
is how its participants compare demographically and
clinically to large-scale efficacy trials of lifestyle modifica-
tion on BP levels [6,7,11,47], and four recently published
effectiveness trials of BP control [34,48-51]. Participation
of African Americans in previous efficacy trials ranged
from 25 to 50% of the sample [6,7,11,34,49,51], while the
CAATCH trial sample consists entirely of African Ameri-
can participants. Of particular note, the CAATCH trial
represents a substantive improvement in African Ameri-
can male participation over previous trials in that almost
one-third of participants were African American men. By
contrast, one-tenth of participants in PREMIER were
African American men. To our knowledge, the CAATCH
trial includes the largest proportion of African American
men in community practice-based trials. Because trust is
a major hindrance to recruitment of minorities into clini-
cal research [52], we adopted a two-pronged strategy to
increase the participation of African American men, in
addition to the traditional compensation provided to
patients. First, we solicited the support of the CHC
patient care coordinators and clerical staff in referring
patients into the study. CHC staff typically interacts with
patients over a longer period of time and have built sig-
nificant rapport and trust with the patients, whereas
research staff have a shorter duration and more circum-
scribed relationship with prospective study participations.
Second, we asked the clinicians to refer their patients
into the trial. This strategy also addresses the issue of
trust, building on the existing relationships between
patients and providers. In addition, we oversampled Afri-
can American men, because women comprise 70% of the
adult users of CHCs. Finally, we held series of educa-
tional sessions at the study sites to inform patients
about the study and to identify and screen potentially
eligible patients; refreshments were offered at these
sessions.
To our knowledge, CAATCH is the largest practice-
based trial of patient and physician targeted interven-
tions for BP control in hypertensive African Americans.
We are only aware of three other trials that have tar-
geted both patients and physicians in practice-based set-
tings [34,49,50]. The first is the HIP trial [34], which is
a nested, 2 × 2 RCT comparing physician intervention,
patient intervention, and both combined versus control
condition, among 574 hypertensive patients in eight pri-
mary care practices (32 physicians) in central North
Carolina. The second is the Veterans Study to Improve
the Control of Hypertension (V-STITCH) trial [49],
which is a 2-level (primary care provider and patient)
cluster RCT among 588 hypertensive patients in a
Veterans Affairs Medical Center primary care clinic (17
physicians) in North Carolina. The third is a study by
Roumie et al., which is a cluster RCT [50] that evaluated
the impact of three quality improvement interventions
(provider education, provider education and alert,
patient education) of increasing intensity among 1,341
hypertensive patients who received care in two hospital-
based and eight community-based outpatient clinics
(182 providers) in the Veterans Affairs Tennessee Valley
Healthcare System. One qualitative difference between
CAATCH and these trials is that CAATCH was focused
exclusively on African Americans. Second, the patients
in CAATCH all had uncontrolled hypertension and
greater co-morbidity than those in the other practice-
based trials. Specifically, CAATCH participants had
higher baseline BP, were more sedentary, had greater
levels of co-morbidity, and higher current smoking rates
than participants in the V-STITCH and HIP trials
[34,49]. Furthermore, CAATCH participants had com-
parable rates of smoking and higher rates of diabetes,
and lower rates of medication adherence than partici-
pants in Roumie et al. VA-based trial of interventions
targeting providers and patients [50]. Perhaps of even
more interest, participants in the CAATCH trial had
lower income than those in the HIP, V-STITCH,
DASH, and PREMIER trials, had less education than
participants in DASH, and PREMIER, and as a group,
were more likely to be underinsured. Thus, the patient
population in CAATCH is more representative of low-
income African Americans with poorly controlled
hypertension and numerous adverse lifestyle behaviors
and clinical characteristics that constitute barriers to
adequate BP control. As such, the findings from
CAATCH will provide needed information on effective-
ness of lifestyle and self-management approaches in care
of this high-risk population in a more generalizable con-
text. Furthermore, the participating CHCs are distribu-
ted widely across upstate New York, four boroughs of
New York City, Northern New Jersey, and serve low-
income, African American patient populations.
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time of recruitment and intervention was relatively low,
and approximately one-half of the CHCs participating in
the trial were involved in the HRSA Health Disparities
Collaborative, an initiative that focuses on improving
access to quality healthcare and improved health out-
comes among medically underserved in order to reduce
or eliminate health disparities [53].
Several strengths of the CAATCH trial deserve con-
sideration. The first is that CAATCH is an evidence-
based multi-level intervention in a very large exclusively
African American practice-based sample, in contrast to
previous efficacy and recent effectiveness trials in which
the rate of African American participation has been
more modest [6,7,11,34,48,54]. Second, CAATCH inclu-
sion criteria allowed for the participation of patients
with uncontrolled BP and those taking multiple medica-
tions, while the exclusion criteria of previous efficacy
s t u d i e s[ 6 , 7 , 1 1 ]w e r em o r ec o n s e r v a t i v eb yc o m p a r i s o n .
Third, CAATCH joins a small number of effectiveness
trials (implemented in the VA [49] or community based
primary care clinics [34]) in efforts to deliver efficacious
treatments in real-world primary care settings.
CAATCH is one of few studies to address barriers to
BP control in this patient population by evaluating the
effectiveness of a practice-based intervention targeted at
patients (home BP monitoring, lifestyle intervention plus
patient education) and physicians (chart audit and feed-
back plus physician education). Thus, findings from this
trial will extend our understanding of applicability and
impact of a multi-level intervention in a population
whose hypertension may be particularly difficult to
control.
We should note the following limitations of the
CAATCH trial. First, similar to other large scale RCTs
in African Americans, majority of CAATCH participants
were women, making the results less generalizable to
African American men. Second, there were imbalances
in several important baseline patient characteristics
between the IC and UC study sites, which raises poten-
tial threats to internal validity of the study findings. The
cluster randomized design of the study sought to mini-
mize baseline differences between both groups via
matching of CHCs based on practice size. The reason
for the observed baseline differences is not clear. One
potential explanation for this imbalance may be the
small number of sites that were randomized rather than
the number of participants. Although the intraclass cor-
relation coefficient (ICC) between the sites on these
variables was quite small [24,55], the additional match-
ing of sites by size may have required larger number of
sites than the proposed 30 sites. Alternative approaches
to mitigate this problem maybe the use of a factorial
design with randomization at the level of the providers
on characteristics, such as number of years practicing in
a community-based setting, size of caseload, and num-
ber of hypertensive patients in current caseload. This is
the approach adopted by Corsino et al.[ 5 6 ] ,w h i c h
often requires matching on lesser number of variables
than sites and manageable number of providers and
patients needed for the study. Other approaches of ran-
domizing at the patient level with matching may also
mitigate this problem, but such an approach is limited
by the potential for contamination that is often a pro-
blematic in practice-based trials using such design, and
the loss of the ability to examine the contribution of
matching variables to changes in study outcomes.
In summary, the demographic and clinical composi-
tion of the CAATCH trial participants represents an
important contribution to the literature on interventions
targeted at poor BP control in a high-risk population.
Namely, the trial includes implementation of a multi-
level, evidence-based, intervention in a real-world setting
among participants who experience multiple demo-
graphic, clinical, psychosocial, and behavioral barriers to
hypertension control. Findings from this trial have
important implications for dissemination and implemen-
tation. First, successful conduct of this study will be an
indication that complex multi-level intervention can be
integrated into care of high-risk hypertensive African
Americans who receive care in CHCs. Second, imbal-
ance noted in the baseline data indicates that investiga-
tors considering cluster RCT design in this patient
population should strongly consider enrolling a larger
number of sites and possibly an alternative design with
randomization at the provider level. Third, recruitment
of this high-risk patient population was achieved with
significant cooperation from the clinical and administra-
tive staff at the participating CHCs. A major lesson
learned in this regard is the underlying assumption that
all CHCs do not operate in the same manner. While
their payment structure may be similar, the staffing in
these sites is quite varied in terms of the use of allied
health providers and availability of health educators who
can provide lifestyle counseling and patient education.
Furthermore, the level of enthusiasm for pragmatic trials
is quite different for each CHC, with some having more
research experience and others lacking experience. This
factor affected recruitment rates, follow-up rates, and
delivery of the intervention. Specifically, sites that were
more research-friendly had the highest completion rates
with easier delivery of the intervention. Future practice-
based research should better characterize the research
sites along these dimensions in order to facilitate imple-
mentation of such complex studies and to assess the
interaction between aspects of study implementation
and CHC trial characteristics. Fourth, implementation of
the patient level component of the intervention,
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af l e x i b l ed e l i v e r yf o r m a t .F o re x a m p l e ,w ef o u n dt h a ta
combination of in-person intervention sessions coupled
with telephone check-in or booster sessions to support
patient up-take of new skills allowed us to improve
treatment fidelity levels.
Conclusions
The CAATCH trial is the first of its kind to focus on
the effectiveness of a multi-level intervention for BP
control in a large, socio-demographically and clinically
diverse sample of hypertensive African American
patients receiving primary care in safety-net settings.
Given characteristics of the CHCs and participants,
CAATCH has the potential to extend our understanding
of barriers and facilitators of BP control in a group that
experiences significant hypertension-related morbidity
and mortality.
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